[return]
Results of a phase III trial of customized adjuvant CT after resection of NSCLC with lymph node metastases. SCAT: a Spanish Lung Cancer Group trial. Massuti B, Rodriguez-Paniagua J.M, Cobo Dols M, Arrabal R, Ballesteros I, Wah Pun Y, Moran T, Lopez De Castro P, González-Larriba J.L, Hernando Trancho F, De Castro J, Diaz-Agüero P, Barneto I, Baamonde C, Ponce S, Martin De Nicolas J.L, Muñoz M.A, Peñalver J, Isla M.D, Rivas De Andres J.J, Lopez-Vivanco G, Pac J, Sanchez J, Sanchez-Paya J, Rosell R.
Oral. Abstract ID: 2983
Brigatinib (AP26113) Efficacy and Safety in ALK+ NSCLC: Phase 1/2 Trial Results
Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss G, Dorer D, Rivera V, Conlan M, Kerstein D, Camidge R.
Oral. Abstract ID: 2125
Detecting ALK, ROS1 and RET fusion genes in advanced non-small cell lung cancer (NSCLC) using a novel multiplexed nCounter-based assay. Reguart N, Gimenez-Capitan A, Molina M.A, Galvan P, Pare L, Viteri S, Teixidó C, Rodriguez S, Castellví J, Aldeguer E, Viñolas N, Rosell R, Prat A.
Mini Oral. Abstract ID: 2254
Transcriptome-metabolome reprogramming of EGFR-mutant lung cancer cells under precision inhibitors contributes to early adaptive drug-escape via mitochondrial priming requiring BCL-Xl Ma P, Thiagarajan P, Zhang W, Wu X, Leahy P, Shi I, Feng Y, Veig M, Lindner D, Danielpour D, Yin L, Zhang Z, Rosell R, Bivona T.
Mini Oral. Abstract ID: 3085